Tislelizumab+liposomal doxorubicin+ifosfamide

4 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Tislelizumab+liposomal doxorubicin+ifosfamide
Treatment and conditionWhere it standsTrials
Tislelizumab+liposomal doxorubicin+ifosfamide for desmoplastic small round cell tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for hemangiosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for leiomyosarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab+liposomal doxorubicin+ifosfamide for liposarcomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1